Close menu

July 29th, 2021 | 13:56 CEST

Alibaba, Memiontec, MorphoSys - Now the rally after the sell-off!

  • Investments
Photo credits:

The regulator's pressure is getting bigger and bigger. China has tightened the thumbscrews on technology giants and especially their online education companies - triggering a stock market quake on its own stock market. In some cases, well-known tech stocks lost double digits, even though the affected areas only affect fractions of annual sales. Government regulation of the USD 100 billion-plus education market is likely to weaken confidence in China's stock markets for the long term. And the fact that China's trade relations with the US have also reached a low point does not make things any better. Are there still opportunities?

time to read: 4 minutes | Author: André Will-Laudien
ISIN: ALIBABA GR.HLDG SP.ADR 8 | US01609W1027 , Memiontec Holdings Limited | SGXE56008290 , MORPHOSYS AG O.N. | DE0006632003

Table of contents:

    Alibaba - Good figures and still punished

    The shares of e-commerce giant Alibaba have now lost a full 40% from their high in February. DZ Bank announced this week that it had lowered its price target from USD 295 to USD 192 and downgraded its vote from "buy" to "sell". The reason given is the massive intervention of the Chinese government in the education market and a quasi-nationalization of the sector. In our opinion, this is somewhat rudimentary and one-sided.

    Alibaba is only marginally involved in the education sector. Chinese founder Jack Ma's Group operates one of the world's largest online trading platforms. The successful website offers customers all daily life products for home, garden, office, cosmetics, sports and entertainment, except food. Alibaba's business units also include the online retailers,, Aliexpress and The Company also offers its online payment system through its financial subsidiary Ant Group. Alibaba is estimated to have a turnover of more than EUR 100 billion in 2021, the EBIT margin is currently 17% - and the Company is growing at a constant rate of 35% per year. So a P/E ratio of 20 is not too expensive.

    But: Since February, Chinese shares have lost USD 1 trio. in stock market value. An end to the slide is not yet in sight; on the contrary: According to a media report, Wall Street is already speculating on further coercive measures by Beijing and possible capital controls. Not a good environment for investors, who currently need a lot of courage. Selectively build up first positions!

    Memiontec - Water treatment for Asia

    Water service provider Memiontec Holdings Ltd is not on the crisis radar. It is a Singapore-based company specializing in all areas of water treatment and purification. For more than 20 years, Memiontec has provided water and wastewater-related services throughout Singapore, Indonesia and the People's Republic of China. Using membrane and ion exchange processes and physical, chemical and biological processes in combination with installation and services, Memiontec covers the entire value chain of water management. Customers are mainly local municipalities and larger industrial companies.

    In June, new orders worth SGD 5.5 million were landed from Indonesia. That brings the current order book to around SGD 81.6 million as of June 30, 2021. The orders fit perfectly into the Group's portfolio and utilize the capacity of the local team in Indonesia. Service providers like Memiontec are a blessing for the populous country, as nearly one in every two Indonesians has no access to clean water. Of Indonesia's 270 million inhabitants, 70% even rely on potentially contaminated sources because there are no alternatives. While Indonesia is not a water-scarce country, limited available water infrastructure, uneven distribution, and rapid economic development have led to water scarcity and high contamination levels in parts of the country, especially in urban areas.

    The greatest water shortage is on Java, Indonesia's most populous island, which is also home to the capital city of Jakarta. The Indonesian government has taken steps to improve the country's infrastructure continuously. Separately, Memiontec has received a commitment from Japan-based Kuraray, an international specialty chemicals manufacturer, to extend exclusive distribution rights for its MBBR technology, which uses polyvinyl alcohol (PVA) gel beads, for the Indonesian market. This adds promise to both Memiontec's pipeline and its technology.

    Far from China and its regulatory frenzy, Singapore-based Memiontec can grow with green projects. It helps the people in the overpopulated region and offers an attractive stock for a sustainable investment via the share listed in Frankfurt.

    MorphoSys - The sell-off could continue

    MorphoSys AG announced an update to its financial guidance for 2021 earlier this week. Based on unaudited consolidated results for the first six months, consolidated revenues are expected to be in the range of EUR 155 to 180 million, compared to a previous corridor of EUR 150 to 200 million. The updated revenue guidance primarily reflects the reduced guidance for Monjuvi product sales.

    MorphoSys also expects a dramatic increase in operating expenses, especially R&D, to a range of EUR 435 to 465 million (previously: EUR 355 to 385 million). The new guidance for the Group's escalating costs is reflected as a result of the acquisition of Constellation Pharmaceuticals, which was completed on July 15, 2021. The total R&D cost ratio is now reported at 57%, which is not surprising for experts, but negative news for the stock market.

    The market was abruptly hit by the sales & profit warning and reinforced the downward trend of recent months. The calculated loss amounts to 64% since one year - the share lost over 17% in the last five trading days alone. Commerzbank speaks of a "loss of confidence" after the sales warning from MorphoSys. Investors had hoped for higher market opportunities for the MorphoSys drug Monjuvi, as this drug is the core of the Company's strategic transition.

    The operating figures after the acquisition are currently not convincing, and the chart situation is also precarious. With a price-to-sales ratio of over 4, the MorphoSys share is still ambitiously valued at EUR 45. Watch!

    The stocks under review here offer a colorful bouquet of investment opportunities, from Chinese uncertainties to justified sell-offs to necessary water technology. Alibaba should be able to pick itself up again, caution is advised with MorphoSys, and Memiontec is, in our opinion, an exciting value from the trend area of environmental technology and infrastructure.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.

    Der Autor

    André Will-Laudien

    Born in Munich, he first studied economics and graduated in business administration at the Ludwig-Maximilians-University in 1995. As he was involved with the stock market at a very early stage, he now has more than 30 years of experience in the capital markets.

    About the author

    Related comments:

    Commented by Juliane Zielonka on September 29th, 2023 | 07:00 CEST

    Defence Therapeutics, Schott Pharma, Allianz Group: Focus on Innovation, Growth and Portfolio Optimization

    • Biotechnology
    • Pharma
    • Investments

    According to a recent study, biotech company Defence Therapeutics achieves twice the immune response of conventional mRNA therapies with its Accum® mRNA technology. That translates to fewer side effects and a more effective treatment. According to Precedence Research, the market size for mRNA therapeutics is projected to reach approximately USD 137.59 billion by 2032. It is expected to grow at a CAGR of 13.2% from 2023 to 2032. In order to inject these active ingredients, precision-fit medical vials are required, and Schott Pharma is ensuring this with their IPO launched on the German stock exchange this week, which could bring a valuation of around EUR 4 billion. The Allianz Group, on the other hand, is focusing on consolidation, selling its business in the Middle East and thus flushing around EUR 210 million cash into its coffers.


    Commented by André Will-Laudien on September 26th, 2023 | 07:45 CEST

    Artificial Intelligence in Sellout! Nvidia, Defense Metals, ARM Holdings - Nothing works without rare earths!

    • Mining
    • RareEarths
    • AI
    • chips
    • Investments

    After long bull market movements, the stock market usually tends to rotate sectors, or the market enters a general consolidation. In the former case, investors can profit by reallocating their assets while exploring new investment opportunities. In the latter case, all stocks come down, and the capital market generally suffers from a change in sentiment and corrects recently exaggerated valuations. In the case of the new megatrend of Artificial Intelligence (AI), the stock market seems to sense a great need for correction. As if by magic, the blockbuster stock Nvidia rose by 250% in just 9 months. However, it has already retraced nearly 20% from its peak. Where do the opportunities lie for investors?


    Commented by André Will-Laudien on September 22nd, 2023 | 07:20 CEST

    Recalculation! These are the bare figures: TUI, Saturn Oil + Gas, Deutsche Bank - Buy prices non-stop!

    • Mining
    • Oil
    • travel
    • Investments
    • Banking

    Companies do not always have good figures in their baggage. Analysts listen very carefully to the words of those in charge. Often, it is only a minor sentence that changes entire valuations. TUI is slowly approaching pre-COVID figures. Saturn Oil & Gas must backtrack slightly because of substantial forest fires in Alberta, and Deutsche Bank aims to finalize the Postbank project in 2023. All three stocks offer good buying opportunities because the long-term prospects are quite convincing.